Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial

Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial

(2021) Alexander J Stratigos et al.   LANCET ONCOLOGY

European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 2. Treatment

(2020) Alexander J. Stratigos et al.   EUROPEAN JOURNAL OF CANCER

Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial

(2020) Michael R Migden et al.   LANCET ONCOLOGY

CA209-9JC: A phase II study of first-line nivolumab (NIVO) in patients (pts) with locally advanced or metastatic cutaneous squamous cell carcinoma.

(2020) Rodrigo Ramella Munhoz et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Study of Pembrolizumab As First-Line, Single-Drug Therapy for Patients With Unresectable Cutaneous Squamous Cell Carcinomas

(2020) Eve Maubec et al.   JOURNAL OF CLINICAL ONCOLOGY

Pembrolizumab Monotherapy for Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: A Single-Arm Phase II Trial (KEYNOTE-629)

(2020) Jean-Jacques Grob et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing

(2020) Danny Rischin et al.   Journal for ImmunoTherapy of Cancer

1084P Cosibelimab, an anti-PD-L1 antibody, in metastatic cutaneous squamous cell carcinoma (mCSCC): Preliminary safety and efficacy results from a phase I clinical trial

(2020) P. Clingan et al.   ANNALS OF ONCOLOGY

Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy

(2019) Paul Nghiem et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II trial of pembrolizumab (MK-3475) in metastatic cutaneous squamous cell carcinoma: An updated analysis.

(2019) Melinda Lynne Yushak et al.   JOURNAL OF CLINICAL ONCOLOGY

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

(2019) Barbara Burtness et al.   LANCET

PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma

(2018) Michael R. Migden et al.   NEW ENGLAND JOURNAL OF MEDICINE

T-Cell–Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028

(2018) Patrick A. Ott et al.   JOURNAL OF CLINICAL ONCOLOGY

Cutaneous Squamous Cell Carcinoma: A Review of High-Risk and Metastatic Disease

(2016) Kyle A. Burton et al.   AMERICAN JOURNAL OF CLINICAL DERMATOLOGY

Management of High-Risk Squamous Cell Carcinoma of the Skin

(2016) Teresa Fu et al.   CURRENT TREATMENT OPTIONS IN ONCOLOGY

Incidence Estimate of Nonmelanoma Skin Cancer (Keratinocyte Carcinomas) in the US Population, 2012

(2015) Howard W. Rogers et al.   JAMA Dermatology

Mutational Landscape of Aggressive Cutaneous Squamous Cell Carcinoma

(2014) C. R. Pickering et al.   CLINICAL CANCER RESEARCH